HOLX - Hologic Inc. (HOLX) Q2 2024 Earnings Call Transcript
2024-05-02 23:24:08 ET
Call Start: 16:30
Call End: 17:24
Hologic, Inc. (HOLX)
Q2 2024 Earnings Conference Call
May 2, 2024 16:30 ET
Company Participants
Ryan Simon - Vice President, Investor Relations
Steve MacMillan - Chairman, President & Chief Executive Officer
Essex Mitchell - Chief Operating Officer
Karleen Oberton - Chief Financial Officer
Conference Call Participants
Patrick Donnelly - Citi
Jack Meehan - Nephron Research
Puneet Souda - Leerink Partners
Casey Woodring - JPMorgan
Andrew Brackmann - William Blair
Andrew Cooper - Raymond James
Presentation
Operator
Good afternoon and welcome to the Hologic Second Quarter Fiscal 2024 Earnings Conference Call. My name is Justin and I am your operator for today's call. Today's conference is being recorded. [Operator Instructions]
I would now like to introduce Ryan Simon, Vice President, Investor Relations, to begin the call.
Ryan Simon
Thank you, Justin. Good afternoon and thank you for joining Hologic's second quarter fiscal 2024 earnings call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; Karleen Oberton, our Chief Financial Officer; and Essex Mitchell, our Chief Operating Officer. Our second quarter press release is available now on the Investors section of our website. We will also post our prepared remarks to our website shortly after we deliver them as well as an updated corporate presentation and a replay of this call will be available on our website for the next 30 days.
Before we begin, we would like to inform you that certain statements we make today will be forward-looking. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the Safe Harbor statement included in our earnings release and SEC filings. Also during this call, we will discuss certain non-GAAP financial measures. A reconciliation to GAAP can be found in our earnings release. Two of these non-GAAP measures are: one, organic revenue which we define as revenue excluding divested businesses and revenue from acquired businesses owned by Hologic for less than 1 year; and two, organic revenue, excluding COVID-19 which further excludes COVID-19 assay revenue, revenue related to COVID-19 and sales from discontinued products in Diagnostics. Finally, any percentage changes we discuss will be on a year-over-year basis and revenue growth rates will be in constant currency unless otherwise noted....
Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript